Zacharon Pharmaceuticals Inc.

Zacharon Pharmaceuticals Inc. focuses on developing innovative glycan-based therapeutics aimed at treating lysosomal storage diseases, rare cancers, and inflammatory conditions through cutting-edge drug discovery platforms. Zacharon Pharmaceuticals Inc. specializes in glycan-targeted therapeutics.

Founded in 2004 in San Diego, US, the company was acquired by BioMarin Pharmaceutical Inc. in January 2012 for USD 10 mn, with potential additional milestone payments. The company has engaged in 2 deals, with the most recent occurring on January 8, 2013. Zacharon Pharmaceuticals develops glycan-based therapeutics, concentrating on small molecule drugs targeting glycans, essential components of biological molecules.

Their drug discovery platform addresses unmet medical needs in various conditions, partnering with organizations like Acorda Therapeutics and Pfizer. Their products cater to healthcare providers, research institutions, and pharmaceutical companies in North America and Europe, and are in various development stages. Zacharon Pharmaceuticals generates revenue primarily through B2B partnerships and collaborations, structuring agreements that include milestone payments and royalties based on product success. The company's revenue model revolves around proprietary therapeutic programs for lysosomal storage diseases and rare cancers, though specific pricing terms are undisclosed.

The company is expected to leverage its recent acquisition by BioMarin Pharmaceutical Inc. to advance its products targeting lysosomal storage diseases and rare cancers. The funding from the trade sale in January 2012, amounting to USD 10 mn, is likely to support ongoing developments and market entry strategies. Future plans involve expanding into new geographic regions, particularly targeting North America and Europe, while continuing to build strategic partnerships to enhance its product pipeline.